<DOC>
	<DOC>NCT00035841</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.</brief_summary>
	<brief_title>Phase 2 Study of TLK286 in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologic diagnosis of breast cancer Metastatic disease Measurable or evaluable disease No prior chemotherapy regimens Age at least 18 years Adequate liver and kidney function Adequate bone marrow function Pregnant or lactating women Unstable medical conditions Chemotherapy within 14 days of TLK286 Radiation therapy within 14 days of TLK286 Hormonal therapy within 14 days of TLK286 Immunotherapy within 14 days of TLK286 CNS metastasis unless controlled by treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>